About the ALBA Study

Finding Paths for Managing the Hypersomnia Journey

You have the power to help awaken possibilities on the journey to find new ways to treat idiopathic hypersomnia (IH). By participating in clinical research, you can use your personal experience with IH to help energize the daily routine for others. See if you qualify for the ALBA Study today.

Finding Paths for Managing the Hypersomnia Journey

You may be able to participate in the ALBA Study if you:

Are 18–70 years of age

Have a diagnosis of IH

Have a BMI between 16 and 38 kg/m²

IH can impose a significant burden on daily life. Researchers are working to identify treatment options that may help individuals with this disorder.

The ALBA Study is evaluating the safety and effectiveness of an investigational drug for IH. During the study, participants will complete up to 7 scheduled study visits over the course of up to 17 weeks, including overnight stays. Study participation will be divided into the following periods:

Screening Period

The screening period lasts up to 45 days before the start of study treatment. During this time, participants will undergo various tests and assessments to determine their eligibility for the study. This includes a review of medical history, a physical examination, and completion of questionnaires about sleep patterns and IH symptoms.

Study Treatment Period

Participants will be randomly assigned to receive either the investigational drug or a placebo (a substance that looks like the investigational drug but does not contain any active ingredients) for 4 weeks. Neither participants nor the study team will know if participants are receiving the investigational drug or a placebo during the study treatment period.

Follow-Up Period

After completing the study treatment period, participants will enter a follow-up period lasting 4 weeks. During this time, participants will have 2 follow-up visits scheduled approximately 1 week and 4 weeks after their last dose of the study drug. These visits will involve monitoring health status and any potential side effects.

Long-Term Extension Period

If a long-term extension study is available for immediate enrollment, and the participant qualifies, the 2 follow-up visits in this study may not be required. Participation in the extension study is voluntary. The long-term extension study provides an opportunity for researchers to gather additional information about the safety and effectiveness of the investigational drug over an extended period.

You can play a role in helping researchers find more ways to study and treat IH by participating in this clinical research study.

See If You May Qualify

Your Participation Matters

Research has shown that certain diseases and drugs may affect people differently based on several factors, including age, sex assigned at birth, race, and ethnic background. For this reason, it is important that people from all backgrounds be involved in medical research. This can help to ensure that potential new drugs are safe and work well for all people impacted by the disease being studied.